Nasdaq

Imara Announces Interim Analysis Data from Forte Phase 2b Clinical Trial of Tovinontrine ...

BOSTON, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects ...
Nasdaq

Imara Presents Preclinical Data on IMR-261 at the American Society of Hematology (ASH ...

Oral presentation provides first look at new program, IMR-261, a novel, oral, clinic-ready nuclear factor erythroid 2-related factor 2 (Nrf2) activator SCD Townes mouse model demonstrates IMR-261 ...